<DOC>
	<DOCNO>NCT02976194</DOCNO>
	<brief_summary>Changes intraocular cytokine include vascular endothelial growth factor ( VEGF ) measure recurrence polypoidal choroidal vasculopathy ( PCV ) treatment ranibizumab .</brief_summary>
	<brief_title>Intraocular Cytokine Recurrence Polypoidal Choroidal Vasculopathy</brief_title>
	<detailed_description>PCV regard subtype age-related macular degeneration ( ARMD ) , several different feature polypoidal terminal new vessel , relative resistance anti-VEGF treatment . Other cytokine VEGF think associate development progression disease . The aim study investigate intraocular cytokine relate recurrence polypoidal choroidal vasculopathy . Aqueous humor sample anterior chamber baseline , load injection ranibizumab recurrence . The concentration various cytokine measure aqueous humor .</detailed_description>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Submacular PCV diagnose base branch neovascular network polypoidal dilatation ICGA . 2 . Presence exudative change involve fovea OCT 3 . Decreased visual acuity 20/320 20/40 primarily result PCV study eye . 4 . Willing able comply clinic visit studyrelated procedure , provide sign informed consent form . 1 . Extramacular PCV . 2 . Presence pathologic change block 50 % area lesion angiography . 3 . Any antiVEGF treatment study eye within 180 day day 1 . 4 . Previous photodynamic therapy study eye . 5 . History intraocular surgery except uncomplicated cataract surgery perform 90 day day 1 . 6 . Presence exudative ARMD require antiVEGF treatment eye . 7 . Presence ocular disease may compromise visual acuity study eye . 8 . Uncontrolled systemic disease . 9 . Active intraocular periocular infection . 10 . Active intraocular inflammation . 11 . Hypersensitivity ranibizumab excipients .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>